Stocktoria
C4 Therapeutics, Inc. CCCC
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-02
C4 Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $35.9M | $35.6M | $20.8M | $31.1M | $45.8M |
| R&D expense | $104.2M | $110.6M | $117.7M | $117.8M | $94.7M |
| Operating income | -$115.2M | -$119.6M | -$139.0M | -$129.5M | -$82.1M |
| Income tax | $121,000 | $131,000 | $1.3M | $0 | $0 |
| Net income | -$105.0M | -$105.3M | -$132.5M | -$128.2M | -$83.9M |
| EPS (diluted) | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 |
| Operating cash flow | -$98.7M | -$65.2M | -$106.8M | -$105.9M | -$87.0M |
| Free cash flow | -$99.3M | -$65.3M | -$108.5M | -$111.4M | -$88.2M |
| Cash & equivalents | $74.6M | $55.5M | $126.6M | $29.8M | $76.1M |
| Total assets | $359.1M | $349.6M | $376.5M | $430.8M | $506.8M |
| Total liabilities | $102.5M | $133.6M | $130.3M | $141.6M | $117.2M |
| Shareholders' equity | $256.6M | $216.0M | $246.1M | $289.2M | $389.6M |
Source: SEC EDGAR filings · CIK 0001662579 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.